Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06233968 · ClinicalTrials.gov registry record
Using Data Science To Center Patient Perspectives in Mechanism Discovery
A clinical trial of Post Traumatic Stress Disorder and Complex Posttraumatic Stress Disorder, sponsored by Cambridge Health Alliance.
- Active
- Registry status
- 33
- Enrollment target
- 1
- Study location
NCT06233968: Active study of Post Traumatic Stress Disorder and Complex Posttraumatic Stress Disorder, sponsored by Cambridge Health Alliance.
NCT06233968 is a study of Post Traumatic Stress Disorder and Complex Posttraumatic Stress Disorder that is active but no longer recruiting, run by Cambridge Health Alliance. The registered enrollment target is 33 participants, below the 664-participant average among 262 other Post Traumatic Stress Disorder trials with a reported enrollment target (95% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06233968, a study of Post Traumatic Stress Disorder and Complex Posttraumatic Stress Disorder, is active but no longer recruiting, sponsored by Cambridge Health Alliance.
- ACTIVE NOT RECRUITING
- Registry status
- 33 participants
- Enrollment target
- 1
- Study location
Study Summary
Including patient perspectives when developing new therapy interventions is crucial because it can help to understand response heterogeneity and promote engagement. Yet, analyzing patient interview data is difficult and time-consuming. This study aims to explore the potential for natural language processing and deep learning to analyze patient interviews and identify potential ways in which therapy leads to psychological change. This study will recruit participants from an existing clinical service that offers a 16-week online group therapy model (and adjunct individual therapy sessions) called Program for Alleviating and Resolving Trauma and Stress (PARTS) based on a therapy called Internal Family Systems (IFS). The investigators will use a mixed methods approach, applying natural language processing and deep learning to develop models that identify potential mechanisms of change. These models will be based on patient perspectives of psychological change, as expressed in interviews, and be compared to models based on clinical measures.
Primary Outcome
Similarity of topics obtained from interview data using language processing tools to those classified by human coders and identification of mechanisms from predictive models with language processing derived features.
Conditions Studied
Study Locations (1)
Massachusetts
- Cambridge Health Alliance - Malden
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 33 participants |
| Start Date | 2024-03-19 |
| Est. Completion | 2026-12-05 |
What the registry record for NCT06233968 still lists
NCT06233968 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 33 participants, a relatively small participant target, below the 664-participant average among 262 other Post Traumatic Stress Disorder trials with a reported enrollment target (95% lower).
The record links to 2 conditions, with Post Traumatic Stress Disorder appearing as the primary indexed condition, and to 0 interventions.
NCT06233968 reports a single indexed study location in Massachusetts.
Frequently Asked Questions
What is clinical trial NCT06233968 about?
NCT06233968 is a clinical study titled "Using Data Science To Center Patient Perspectives in Mechanism Discovery". Including patient perspectives when developing new therapy interventions is crucial because it can help to understand response heterogeneity and promote engagement. Yet, analyzing patient interview data is difficult and time-consuming. This study aims to explore the potential for natural language pr...
What is the current status of trial NCT06233968?
This trial is currently active not recruiting. The enrollment target is 33 participants. The study started on 2024-03-19. Estimated completion is 2026-12-05.
What conditions does trial NCT06233968 study?
This clinical trial studies the following conditions: Post Traumatic Stress Disorder, Complex Posttraumatic Stress Disorder.
Who is sponsoring clinical trial NCT06233968?
This trial is sponsored by Cambridge Health Alliance, which has 45 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06233968 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Post Traumatic Stress Disorder
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06233968's enrollment target sits among peer trials
33 204th of 262 higher than 58 of 262 other Post Traumatic Stress Disorder trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Post Traumatic Stress Disorder trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Exploring Virtual Reality Adventure Training Exergaming
RECRUITING · NA
-
Department of Defense PTSD Adaptive Platform Trial - Intervention A - Fluoxetine
RECRUITING · Phase 2
-
CRISOL Mente: A Multilevel Community Intervention to Reduce Mental Health Disparities Among Latinos
RECRUITING · NA
-
TMS-fNIRS Personalized Dosing
RECRUITING · NA
-
Targeting the Default Mode Network: A TMS-fMRI Study
RECRUITING · NA
-
The Effects of Very Brief Exposure on PTSD in U.S. Combat Veterans
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02861898 · 33 participants · Phase 1
Super-selective Intra-arterial Repeated Infusion of Cetuximab for the Treatment of Newly Diagnosed Glioblastoma
- NCT04871607 · 33 participants · Phase 2
Yttrium-90 Labeled Anti-CD25 Monoclonal Antibody Combined With BEAM Chemotherapy Conditioning for the Treatment of Primary Refractory or Relapsed Hodgkin Lymphoma
- NCT05071937 · 33 participants · Phase 2
ZEN003694 Combined With Talazoparib in Patients With Recurrent Ovarian Cancer
- NCT05168618 · 33 participants · Phase 2
Cabozantinib and Atezolizumab for the Treatment of Metastatic Castration-Resistant Prostate Cancer, The AtezoCab Trial
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI